The standard regimen of the BNT162b2 mRNA vaccine for SARS-CoV-2 includes two doses administered three weeks apart. However, some public health authorities spaced these doses, raising questions about efficacy. We analyzed longitudinal humoral responses against the D614G strain and variants of concern for SARS-CoV-2 in a cohort of SARS-CoV-2-naive and previously infected individuals who received the BNT162b2 mRNA vaccine with sixteen weeks between doses. While administering a second dose to previously infected individuals did not significantly improve humoral responses, these responses significantly increased in naive individuals after a 16-week spaced second dose, achieving similar levels as in previously infected individuals. Comparing these responses to those elicited in individuals receiving a short (4-week) dose interval showed that a 16-week interval induced more robust responses among naive vaccinees. These findings suggest that a longer interval between vaccine doses does not compromise efficacy and may allow greater flexibility in vaccine administration.

用于 SARS-CoV-2 的 BNT162b2 mRNA 疫苗的标准方案包括两剂间隔三周的疫苗。然而，一些公共卫生当局将这些剂量间隔开来，引发了对疗效的质疑。我们分析了一组未感染 SARS-CoV-2 和之前感染过 BNT162b2 mRNA 疫苗且间隔 16 周的个体对 D614G 毒株和 SARS-CoV-2 相关变体的纵向体液反应。虽然对先前感染的个体施用第二剂并没有显着改善体液反应，但在 16 周间隔的第二剂后，这些反应在未接受治疗的个体中显着增加，达到与先前感染的个体相似的水平。将这些反应与接受短（4 周）剂量间隔的个体引起的反应进行比较表明，16 周的间隔在未接种疫苗的人中引起更强烈的反应。这些发现表明，疫苗剂量之间较长的间隔不会影响功效，并且可能使疫苗接种具有更大的灵活性。